Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT)

Ohri, Nitin; Jolly, Shruti; T. Cooper, Benjamin; Kabarriti, Rafi; Bodner, William; Klein, Jonathan; Guha, Chandan; Shankar, V.; Shum, Elaine; K. Sabari, Joshua; Cheng, Haiying; Gucalp, Rasim; Castellucci, Enrico; Qin, Angel; M. Gadgeel, Shirish; Halmos, Balázs

doi:10.1200/jco.23.00627

Public

Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT)

Published in Journal of Clinical Oncology • Nov 21, 2023

Authors:

Nitin Ohri

Shruti Jolly

Benjamin T. Cooper

Abstract

PURPOSE: Standard therapy for locally advanced non-small-cell lung cancer (LA-NSCLC) is concurrent chemoradiotherapy followed by adjuvant durvalumab. For biomarker-selected patients with LA-NSCLC, we hypothesized that sequential pembrolizumab and risk-adapted radiotherapy, without chemotherapy, woul...

Subject

Medicine

Pembrolizumab

Durvalumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!